Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma

Figure 1

(a) Time to progression (TTP), (b) progression-free survival (PFS), and (c) overall survival (OS) of patients who received bortezomib retreatment. The median TTP was 5.8 months (95% CI: 2.6–9.0), median PFS was 5.8 months (95% CI: 4.2–6.8), and median OS was 13.4 months (95% CI: 6.1–20.7).

(a)

(b)

(c)